Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies. © 2014 Elsevier Inc.
Cohen, R. L., & Settleman, J. (2014, June 19). From cancer genomics to precision oncology - Tissue’s still an issue. Cell. Cell Press. https://doi.org/10.1016/j.cell.2014.05.027